---
layout: default
title: Oxybutynin
description: "Oxybutynin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 120
evidence_level: L5
indication_count: 3
---

# Oxybutynin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Oxybutynin è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Oxybutynin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Oxybutynin ç‚ºæŠ—è†½é¹¼è—¥ç‰©ï¼ŒåŸç”¨æ–¼è†€èƒ±éå‹•ç—‡ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æŸäº›è…¸èƒƒé“ç–¾ç—…æœ‰æ½›åœ¨æ‡‰ç”¨ï¼Œä½†ç›®å‰ç¼ºä¹ç›´æ¥è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“åç¨± | Oxybutynin (ç¾¥å¸ƒæ‰˜å°¼/å¥§æ–¯å¿…å¾—å¯§) |
| DrugBank ID | DB01062 |
| å°ç£å•†å“å | é”å¤šå¹«éŒ ã€å®‰è–„æ±—æ“¦åŠ‘ã€æ­ä¿å°¿å…‹è²¼å¸ƒç­‰ |
| åŸé©æ‡‰ç—‡ | è†€èƒ±éå‹•ç—‡ã€åŸç™¼æ€§æ‰‹æŒå¤šæ±—ç—‡ã€è†€èƒ±ç¥ç¶“æ§åˆ¶ä¸é©ä¼´éš¨æ’å°¿ç—‡ç‹€ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | cauda equina syndromeã€overactive bladder (disease)ã€restless legs syndrome |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬) |
| TxGNN é æ¸¬åˆ†æ•¸ | é«˜åˆ†é æ¸¬ |

---

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### æ©Ÿè½‰é€£çµ

1. **æŠ—è†½é¹¼ä½œç”¨**ï¼šOxybutynin ç‚ºè•ˆæ¯’é¹¼å—é«”æ‹®æŠ—åŠ‘ (M1-M3)ï¼Œå¯æŠ‘åˆ¶å¹³æ»‘è‚Œæ”¶ç¸®ã€‚æ­¤æ©Ÿè½‰é™¤äº†ä½œç”¨æ–¼è†€èƒ±é€¼å°¿è‚Œå¤–ï¼Œç†è«–ä¸Šä¹Ÿå¯èƒ½å½±éŸ¿è…¸èƒƒé“å¹³æ»‘è‚Œã€‚

2. **å‰¯äº¤æ„Ÿç¥ç¶“æŠ‘åˆ¶**ï¼šå°ç£ TFDA æ ¸å‡†é©æ‡‰ç—‡åŒ…å«ã€Œå‰¯äº¤æ„Ÿç¥ç¶“æŠ‘åˆ¶è—¥ã€ï¼Œé¡¯ç¤ºå…¶å°å‰¯äº¤æ„Ÿç¥ç¶“ç³»çµ±çš„å»£æ³›ä½œç”¨ã€‚

---

## è‡¨åºŠè©¦é©—è­‰æ“š

ç›®å‰ç„¡é‡å°é æ¸¬æ–°é©æ‡‰ç—‡çš„å·²å®Œæˆè‡¨åºŠè©¦é©—ã€‚

---

## æ–‡ç»è­‰æ“š

ç›®å‰è³‡æ–™åº«ä¸­ç„¡ç›´æ¥æ”¯æŒé æ¸¬æ–°é©æ‡‰ç—‡çš„ PubMed æ–‡ç»ã€‚

---

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | é©æ‡‰ç—‡ | ç‹€æ…‹ |
|-----------|--------|------|--------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028910è™Ÿ | å®‰è–„æ±—æ“¦åŠ‘ 20% | æ“¦åŠ‘ | åŸç™¼æ€§æ‰‹æŒå¤šæ±—ç—‡ (12æ­²ä»¥ä¸Š) | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028008è™Ÿ | æ­ä¿å°¿å…‹å¿«é©è²¼å¸ƒ | è²¼å¸ƒ | è†€èƒ±éå‹•ç—‡ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬027361è™Ÿ | é”å¤šå¹«éŒ  5mg | éŒ åŠ‘ | è†€èƒ±ç¥ç¶“æ§åˆ¶ä¸é©ä¼´éš¨æ’å°¿ç—‡ç‹€ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬035278è™Ÿ | å„ªæ¨‚æ§éŒ  5mg | éŒ åŠ‘ | è†€èƒ±ç¥ç¶“æ§åˆ¶ä¸é©ä¼´éš¨æ’å°¿ç—‡ç‹€ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬057414è™Ÿ | æ³Œåœç·©é‡‹éŒ  5mg | ç·©é‡‹éŒ  | è†€èƒ±éå‹•ç—‡ (æ€¥å°¿ã€é »å°¿ã€æ€¥è¿«æ€§å°¿å¤±ç¦) | æœ‰æ•ˆ |

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è­¦èª

- **æŠ—è†½é¹¼å‰¯ä½œç”¨**ï¼šå£ä¹¾ã€ä¾¿ç§˜ã€è¦–åŠ›æ¨¡ç³Šã€å°¿æ»¯ç•™ã€å¿ƒè·³åŠ é€Ÿ
- **ä¸­æ¨ç¥ç¶“ç³»çµ±å½±éŸ¿**ï¼šå¯èƒ½é€ æˆèªçŸ¥åŠŸèƒ½éšœç¤™ï¼Œç‰¹åˆ¥æ˜¯è€å¹´äºº
- **ç†±èª¿ç¯€éšœç¤™**ï¼šæ¸›å°‘å‡ºæ±—å¯èƒ½å°è‡´ä¸­æš‘é¢¨éšªå¢åŠ 

### è—¥ç‰©äº¤äº’ä½œç”¨ (Major)

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | ä¾†æº |
|-------------|----------|------|
| Potassium chloride | Major | DDInter |

### è—¥ç‰©äº¤äº’ä½œç”¨ (Moderate)

| äº¤äº’ä½œç”¨è—¥ç‰© | èªªæ˜ |
|-------------|------|
| Eluxadoline | å¯èƒ½å¢å¼·æŠ—è†½é¹¼ä½œç”¨ |
| Trospium | æŠ—è†½é¹¼ä½œç”¨ç–ŠåŠ  |
| Mepenzolate | æŠ—è†½é¹¼ä½œç”¨ç–ŠåŠ  |
| Methscopolamine | æŠ—è†½é¹¼ä½œç”¨ç–ŠåŠ  |
| Metoclopramide | è—¥æ•ˆå¯èƒ½ç›¸äº’æ‹®æŠ— |
| Scopolamine | æŠ—è†½é¹¼ä½œç”¨ç–ŠåŠ  |
| Pramlintide | å¯èƒ½å½±éŸ¿èƒƒæ’ç©º |

### ç‰¹æ®Šæ—ç¾¤

- **è€å¹´äºº**ï¼šå¢åŠ èªçŸ¥éšœç¤™é¢¨éšªï¼Œæ‡‰è¬¹æ…ä½¿ç”¨
- **é–‰è§’å‹é’å…‰çœ¼æ‚£è€…**ï¼šç¦å¿Œä½¿ç”¨
- **é‡ç—‡è‚Œç„¡åŠ›æ‚£è€…**ï¼šå¯èƒ½åŠ é‡ç—‡ç‹€
- **å°¿é“é˜»å¡æ‚£è€…**ï¼šå¯èƒ½åŠ é‡å°¿æ»¯ç•™

---

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šUse of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be...
- å»ºè­°ï¼šAlcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect the...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Parkinson Disease** ğŸŸ¡ Moderate
- Oxybutynin is associated with anticholinergic central nervous system (CNS) effects.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Oxybutynin should be used with caution in patient...

**Diabetic Neuropathies** ğŸŸ¢ Minor
- Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in mal...

**Dysentery** ğŸŸ¢ Minor
- The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous e...

**Glaucoma, Angle-Closure** ğŸŸ¢ Minor
- The use of oxybutynin is contraindicated in patients with uncontrolled angle-closure (narrow angle) or narrow anterior chamber glaucoma.  Oxybutynin exerts anticholinergic activity (1/5 that of atropine) and can result in increased intraocular pressu...

**Intestinal Obstruction** ğŸŸ¢ Minor
- The use of oxybutynin is contraindicated in patients with GI obstruction, ileus, atony, megacolon, toxic megacolon associated with ulcerative colitis, severe colitis, and obstructive uropathy.  Oxybutynin exerts direct antispasmodic effects on smooth...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°

Oxybutynin å°é æ¸¬æ–°é©æ‡‰ç—‡çš„æ”¯æŒè­‰æ“šæ¥µç‚ºæœ‰é™ï¼š

1. **è­‰æ“šç­‰ç´šæœ€ä½ (L5)**ï¼šåƒ…æœ‰ TxGNN æ¼”ç®—æ³•é æ¸¬ï¼Œç„¡è‡¨åºŠæˆ–å‰è‡¨åºŠè­‰æ“š
2. **æ©Ÿè½‰é€£çµè–„å¼±**ï¼šæŠ—è†½é¹¼ä½œç”¨å¯èƒ½æœ‰ç†è«–ä¸Šçš„é—œè¯ï¼Œä½†ç¼ºä¹é©—è­‰
3. **å®‰å…¨æ€§è€ƒé‡**ï¼šå·²çŸ¥å‰¯ä½œç”¨è¼ƒå¤šï¼Œç‰¹åˆ¥æ˜¯å°è€å¹´äººç¾¤

### å»ºè­°è¡Œå‹•

- **éœ€è¦æ›´å¤šåŸºç¤ç ”ç©¶**ï¼šå»ºç«‹æ©Ÿè½‰å‡èªªçš„è­‰æ“šåŸºç¤
- **è©•ä¼°é¢¨éšªæ•ˆç›Šæ¯”**ï¼šè€ƒæ…®åˆ°å·²çŸ¥å‰¯ä½œç”¨ï¼Œéœ€è¦å¼·åŠ›çš„ç™‚æ•ˆè­‰æ“šæ‰å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶
- **å„ªå…ˆä½¿ç”¨ç¾æœ‰é©æ‡‰ç—‡**ï¼šç›®å‰é©åˆç”¨æ–¼å…¶å·²æ ¸å‡†çš„è†€èƒ±ç›¸é—œé©æ‡‰ç—‡

---

*æœ¬å ±å‘Šç”± TxGNN é æ¸¬ç³»çµ±ç”Ÿæˆï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Potassium Iodide]({{ "/drugs/potassium_iodide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Paclitaxel]({{ "/drugs/paclitaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamethazine]({{ "/drugs/sulfamethazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Oxybutyninè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/oxybutynin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_oxybutynin,
  title = {Oxybutyninè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/oxybutynin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
